has been cited by the following article(s):
[1]
|
Phase 3 efficacy and safety trial of proposed liraglutide biosimilar for reduction of glycosylated hemoglobin (HbA1c) in patients with Type 2 diabetes mellitus
Diabetes Research and Clinical Practice,
2024
DOI:10.1016/j.diabres.2023.111034
|
|
|